Reference market
Open- Regular hours
- 09:30 AM – 04:00 PM EST
- Next holiday
- Nov 26, 2026 · Thanksgiving Day
Equity
Novo Nordisk A/S (NVO) perpetual futures
NVO perpetual futures on 16 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade NVOUSDT.
Global pharmaceutical firm researching, developing, manufacturing and selling medicines, plus devices like insulin pens, across several regions.
$41.06+1.0%NYSE open
Price chart
Interactive TradingView chart
TradingView symbol NYSE:NVO
Loads TradingView's third-party widget (about 1 MB) on demand.
Auto: underlying reference priceOpen in TradingView
Trading data
Perpetual market activity
16/16 live markets
Trading data
Perpetual market activity
Venues
16
Live markets
16/16
24h volume
$3.8M
Open interest
$3.6MCoverage: 13/16 markets
Best liquidity
$1.3M
Bitunix
Tightest spread
+2.4 bps
Bitunix
Highest volume
$742.7K
BingX
Settlement mix
USDT · 15/16
Perp/spot vol.
0.01x
Spot volume $642.6M
OI / float
0.00%
Float $129.6B
Spot performance
1D-1.07%
5D+2.24%
1M+6.81%
6M-13.66%
YTD-20.11%
1Y-17.31%
Venue matrix
16 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Binance | Trade | NVO/USDT | Trading | $41.05 | +13.6% APR +0.012% every 8h | +7.3 bps | $505.9K | $494.2K | $912.9K | USDT | - | |
 Ourbit | Trade | NVO/USDT | Trading | $41.05 | +13.8% APR +0.013% every 8h | +4.9 bps | $791.5K | $479.7K | $116.3K | USDT | 50x | |
 Deepcoin | Trade | NVO/USDT | Trading | $41.05 | - | +7.3 bps | $204.2K | $451.3K | $28.7 | USDT | 25x | |
 KuCoin | Trade | NVO/USDT | Trading | $41.13 | 0.0% APR 0.000% every 8h | +34.1 bps | $3.8K | $205.1K | $357.1K | USDT | 10x | |
 Gate.io | Trade | NVO/USDT | Trading | $41.01 | 0.0% APR 0.000% every 8h | +46.3 bps | $25.8K | $172.4K | $169.9K | USDT | 20x | |
 LBank | Trade | NVO/USDT | Trading | $41.05 | +13.9% APR +0.013% every 8h | +7.3 bps | $324.5K | $172.3K | $75.9K | USDT | 50x | |
 GRVT | Trade | NVO/USDT | Trading | $41.06 | +21.1% APR +0.019% every 8h | +12.2 bps | $200.2K | $108K | $1.1K | USDT | - | |
 MEXC | Trade | NVO/USDT | Trading | $41.04 | +13.8% APR +0.013% every 8h | +9.7 bps | $368.2K14 min | $107K | $1.1M | USDT | 50x | |
 Bitunix | Trade | NVO/USDT | Trading | $41.06 | +18.4% APR +0.017% every 8h | +2.4 bps | $1.3M | $83.8K | $29.9K | USDT | 50x | |
 OKX | Trade | NVO/USDT | Trading | $41.08 | 0.0% APR 0.000% every 8h | +16.6 bps | $17.2K | $75.6K | $111.8K | USDT | 20x | |
 Helix (Injective) | Trade | NVO/USDC | Trading | $41.01 | +24.1% APR +0.00275% every 1h | +738.6 bps | $0 | $65.7K | - | USDC | 12x | |
 Bybit | Trade | NVO/USDT | Trading | $41.07 | 0.0% APR 0.000% every 8h | +19.5 bps | $29.4K | $22.5K | $690.9K | USDT | 25x | |
 HTX | Trade | NVO/USDT | Trading | $41.08 | 0.0% APR 0.000% every 8h | +34.1 bps | $39.2K | $9.9K | $13.9K | USDT | - | |
 Aster | Trade | NVOUSDT | Trading | $41.04 | 0.0% APR 0.000% every 8h | +19.5 bps | $80.6K | $1.7K | $3.3K | USDT | - | |
 BingX | Trade | NVO-USDT | Trading | $41.06 | +15.3% APR +0.014% every 8h | +7.3 bps | $786.1K | $742.7K | - | USDT | - | |
 XT.com | Trade | NVO/USDT | Trading | $41.02 | +11.0% APR +0.010% every 8h | +7.3 bps | $22.4K | $573.6K | - | USDT | 20x |
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| NVOonOndo GM | $41.95 | +2.16% | $852k | $2.1M | Ethereum · BNB Smart Chain (BEP20) · Solana |
| NVOXxStocks | $40.71 | -0.84% | $4k | $547k | Solana · Arbitrum · BNB Smart Chain (BEP20) · Ink |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 14 of 16 venues absorb $10k · Typical cost: +11.5 bps – +46.0 bps
Too thin: KuCoin
No fresh book data: Helix (Injective)
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
NVOTightest spread
NVOHighest volume
NVOFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2027-02-03
Revenue est. $11.8B · Updated 3h ago
Dividend
$0.58
2026-08-17
No unusual perp activity right now.
Reference data
Market context
Reference data
Market context
New York Stock Exchange
Extended-hours reference
Bid40.92
Ask40.93
Volume2,613,481
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 20263.40$45.9B0%6
FY 20273.35$46.7B+2%7
FY 20283.63$49.5B+6%4
FY 20293.97$53.2B+8%2
FY 20304.32$55.7B+5%4
Q3 20260.72$11B-1%3
Source: FMP · Consensus
Company events
62027-02-03EarningsActual - / Estimate 0.68-
2026-11-04Earnings · Before market openActual 0.89 / Estimate 0.731Beat
2026-08-17Dividend$0.579-
2026-08-05EarningsActual 0.96 / Estimate 0.82Beat
2026-05-06EarningsActual 1.04 / Estimate 0.87Beat
2026-03-30Dividend$1.217-
Peer comparison
Similar listed perpsRevenue mix
Latest annualNorth AmericaGeographickr 136.6B
EMEAGeographickr 50.9B
Rest of WorldGeographickr 28.1B
Analysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $42.33 |
| 12-month target range (low – high) | $40 – $47 |
| Ratings in the provider's consensus | 39 |
Price targets as of 2026-11-12
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 0 | 3 | 10 | 1 | 0 |
| Oct 2026 | 0 | 3 | 10 | 1 | 0 |
| Sep 2026 | 0 | 3 | 11 | 1 | 0 |
| Aug 2026 | 0 | 4 | 11 | 0 | 0 |
| Jul 2026 | 0 | 4 | 10 | 0 | 0 |
| Jun 2026 | 1 | 4 | 10 | 0 | 0 |
| May 2026 | 1 | 4 | 9 | 0 | 0 |
| Apr 2026 | 1 | 4 | 9 | 0 | 0 |
| Mar 2026 | 1 | 6 | 9 | 1 | 0 |
| Feb 2026 | 1 | 6 | 5 | 2 | 0 |
| Jan 2026 | 1 | 6 | 5 | 2 | 0 |
| Dec 2025 | 1 | 6 | 4 | 2 | 0 |
Ownership
Institutional · 2026-Q3Free float71.2%3.2B shares
Shares outstanding4.4B shares
Institutional3.6%943 investors
Investor count change-518
Reference market activity
NVO-PERPDay range (Nov 12)$40.09$41.01
52 week$35.12$64.16
Spot volume15.6M
Average volume-
Price performance
111D-1.1%
5D+2.2%
1M+6.8%
3M-13.0%
6M-13.7%
YTD-20.1%
1Y-17.3%
3Y-59.7%
5Y-28.4%
10Y+146.5%
MAX+25,306.3%
Insider activity
No insider data available.No insider data available.
Filings
56 · Latest SEC filingsTranscripts
Earnings callsFY2026 Q12026-05-06
Earnings calls
AI summary
positiveNovo Nordisk delivered mixed Q1 2026 results with adjusted sales declining 4% at CER due to price erosion, but raised 2026 guidance citing stronger-than-expected oral Wegovy uptake, Wegovy HD approval, and international expansion. The company is treating over 4 million obesity patients (up 50% YoY) with 1 million using Wegovy pill since launch 16 weeks ago, though facing headwinds from Medicaid coverage reductions and intensifying competition.
Key takeaways
- Wegovy pill generated 2 million prescriptions and 1 million patients since launch 16 weeks ago, with 207,000 weekly prescriptions by late April; 80% of users are GLP-1 treatment-naive
- Adjusted sales guidance for 2026 raised to -4% to -12% (from prior -4% to -14%) driven by increased GLP-1 confidence; adjusted operating profit guidance similarly raised to -4% to -12%
- Obesity care sales surged 22% with international up 44% and U.S. up 9%; GLP-1 diabetes sales declined 11% as U.S. operations fell 11% partially offset by 6% international growth
- Company achieved 6 regulatory approvals and 10+ clinical trial initiations in Q1; obtained FDA approvals for Wegovy 7.2mg HD and Etavopivat for sickle cell disease, with Etavopivat regulatory submission planned Q4 2026
Financial highlights
- Reported sales increased 32% to DKK 96.8 billion; adjusted sales declined 4% at CER driven by lower realized prices partly offset by GLP-1 volume growth and market expansion
- Adjusted gross margin decreased to 80.6% from 83.5% in 2025, reflecting lower realized prices, onetime costs, and negative currency impact partially offset by GLP-1 positive product mix
- Adjusted operating profit decreased 6% at CER; company returned DKK 38 billion to shareholders through dividends and buybacks while investing DKK 22 billion in R&D and commercial initiatives
- Wegovy pill sales contributed approximately DKK 2.3 billion in Q1 with roughly $150 million related to pipeline inventory filling; international obesity care sales reached DKK 9.2 billion
Guidance
- 2026 adjusted sales growth guidance: -4% to -12% at CER (raised 1 percentage point from prior -4% to -14%)
- 2026 adjusted operating profit growth: -4% to -12% at CER (raised 1 percentage point from prior range)
- Guidance assumes continued GLP-1 volume growth, negative impact from semaglutide patent expiry in certain markets, reduced Medicaid obesity coverage, pricing pressure from Most-Favored-Nations agreement, and Wegovy pill market penetration assumptions
- Company expects Wegovy FlexTouch resubmission decision in U.S. Q1, EU decisions on Wegovy pill and 7.2mg single-dose device, CagriSema U.S. decision end of 2026 with potential 2027 launch, and Etavopivat regulatory submission Q4 2026
Q&A themes
- Oral Wegovy pricing at 'sweet spot' with 2 million scripts in 16 weeks despite competitors launching; dynamic pricing may shift for hundreds of millions of patients long-term
- Titration to higher Wegovy pill doses occurring as expected with week-over-week uptake toward 9 and 25mg doses; uptake comparable to injectable Wegovy with margins similar to 2.4mg on safety
- Supply constraints on Wegovy pill prevent unlimited international launches but company already announcing select ex-U.S. market launches H2 2026; gradual rollout planned
- R&D investment expected to increase in coming quarters after Q1 being on 'low side'; two tri-agonist programs (GLP-1/GIP/glucagon and GLP-1/GIP/amylin) will both advance with Phase II UBT251 data showing stellar weight loss, internal tri-agonist Phase II data coming 2027
Risks
- U.S. GLP-1 diabetes sales declining 11% YoY with pricing pressure from Most-Favored-Nations agreement with U.S. administration; Medicaid coverage reductions for obesity medications creating headwinds
- Generic semaglutide competition emerging with 2 approved generics in Canada and approvals in India; potential for 65% price decline after 3 generics in Canada; international market share declining though stabilizing
- Ziltivekimab (ZEUS, HERMES, ARTEMIS trials) flagged as first-in-class with 'high risk' requiring proof of efficacy, safety and tolerability of anti-IL-6 despite 'high potential' in three cardiovascular indications
FY2025 Q42026-02-04
Earnings calls
AI summary
mixedNovo Nordisk delivered 10% sales growth and 6% operating profit growth in 2025, driven by obesity care sales reaching DKK 82 billion, a 134% increase in Wegovy sales, and the successful December 2025 FDA approval and January 2026 launch of the Wegovy pill. However, the company guided for FY2026 adjusted sales decline of 5-13% at constant exchange rates, reflecting anticipated pricing pressure from most-favored-nations agreements, Medicaid coverage losses, and semaglutide loss of exclusivity in certain International markets, partially offset by expected volume growth from the Wegovy pill and expanded obesity treatment reach.
Key takeaways
- Wegovy pill launched January 5, 2026 with exceptional uptake of ~50,000 prescriptions in first four weeks, positioning it as the leading anti-obesity medication franchise in the U.S.
- CagriSema Phase III REIMAGINE 2 data demonstrated superior A1c reduction of 1.91 percentage points and 14.2% weight loss versus semaglutide 2.4mg in type 2 diabetes.
- Zenagamtide Phase II data showed up to 1.8 percentage points A1c reduction with once-weekly dosing, supporting advancement to Phase III AMBITION program in H2 2026.
- FY2026 adjusted sales guidance of -5% to -13% reflects low single-digit International Operations growth offset by high single-digit U.S. sales decline driven by pricing investments and MFN agreement impacts.
- Company treating nearly 46 million people globally; returned over DKK 300 billion to shareholders since 2019 and proposed 2.6% dividend increase for 30th consecutive year.
Financial highlights
- FY2025 sales grew 10% at constant exchange rates to reach record levels; obesity care sales increased 31% to DKK 82 billion with Wegovy sales up 134% to DKK 28 billion
- Operating profit increased 6% at constant exchange rates; declined 1% in Danish kroner due to DKK 8 billion company-wide restructuring costs
- Gross margin decreased to 81% from 84.7% in 2024, impacted by amortization from Catalent acquisition and restructuring costs
- Generated DKK 120 billion in operating cash flow in 2025; capital expenditure expected ~DKK 55 billion in 2026 with projected decline in coming years
Guidance
- FY2026 adjusted sales growth expected -5% to -13% at constant exchange rates; reported growth in Danish kroner expected ~3 percentage points lower
- FY2026 adjusted operating profit growth expected -5% to -13% at constant exchange rates; reported growth in Danish kroner expected ~5 percentage points lower
- Free cash flow expected DKK 35-45 billion in 2026; total shareholder returns anticipated exceeding DKK 60 billion including new DKK 15 billion share repurchase program
- Medicare Part D Wegovy coverage anticipated to begin around mid-2026 with gradual ramp and limited benefit in 2026, larger benefit anticipated in 2027; REDEFINE 1 results expected Q1 2026; semaglutide 7.2mg FDA decision anticipated Q1 2026
Q&A themes
- Guidance conservatism reflects uncertainty around obesity market dynamics including competitive launches, cannibalization effects between pill and injectable, and self-pay channel price elasticity; company expects volume response to lower prices but acknowledges multiple variables
- Wegovy pill gross margin below injectable but remains attractive; company positioning pill to expand market rather than cannibalize, with expectations that majority of early adopters are new to obesity medications
- MFN pricing impact represents low single-digit sales headwind to group; Ozempic MFN and MFP impact more of 2027 event; company plans to re-engage states on Medicaid coverage given lower available prices
- Supply confidence affirmed for both injectable and pill Wegovy through 2026; API build-out on track with major facilities coming online this year; 7.2mg Wegovy high dose to launch immediately upon FDA approval expected Q1 2026
Risks
- FY2026 pricing headwinds from MFN agreements, Medicaid coverage reductions in multiple states, and semaglutide loss of exclusivity in International markets present significant revenue decline risk; company guidance range of -5% to -13% reflects uncertainty
- Obesity market highly dynamic with competitive pressures from tirzepatide and incoming orforglipron; Wegovy pill early uptake data spans only four weeks; cannibalization risks between pill and injectable formulations, and between Novo products and competitors remain uncertain
- Executive departures of Dave Moore and Ludovic Helfgott create transition risk; company also faces generic semaglutide competition timeline uncertainty in Canada and other markets pending Health Canada approval resolutions
FY2025 Q32025-11-05
Earnings calls
AI summary
mixedThe company delivered 15% sales growth and 46 million patients treated in the first nine months of 2025, driven by strong obesity care growth (41%) and GLP-1 diabetes expansion. However, management narrowed 2025 guidance to 8-11% sales growth and 4-7% operating profit growth, citing competitive headwinds in both diabetes and obesity markets. Novo Nordisk is executing a company-wide transformation involving 9,000 job cuts and pursuing acquisitions including Akero, Omeros' zaltenibart assets, and a revised offer for Metsera to bolster its obesity and diabetes pipeline.
Key takeaways
- 9M 2025 sales grew 15% at constant exchange rates; global market share in combined GLP-1 diabetes/obesity market declined significantly over 12 months
- Obesity care sales surged 41%, with Wegovy reaching approximately DKK 20 billion in international operations (168% growth) and 25% growth in U.S. operations
- Company-wide transformation underway with ~9,000 position reductions expected to generate DKK 8 billion in annual savings by end of 2026, to be redeployed to diabetes and obesity franchises
- Submitted revised acquisition proposal for Metsera at USD 62.2 per share upfront plus up to USD 2.8 billion in contingent value rights; also agreed to acquire Akero and Omeros' zaltenibart assets
Financial highlights
- 9M 2025 sales: 15% growth at constant exchange rates (12% in DKK); operating profit grew 10% at constant exchange rates (5% in DKK)
- Gross margin declined to 81.0% from 84.6% in 2024, impacted by ~DKK 3 billion restructuring costs and production asset impairments
- Free cash flow: DKK 63.9 billion in 9M 2025 vs DKK 71.8 billion in 9M 2024; returned DKK 53 billion to shareholders primarily through dividends
- Full-year 2025 guidance: 8-11% sales growth and 4-7% operating profit growth at constant exchange rates; capex now expected ~DKK 60 billion; free cash flow guidance DKK 20-30 billion
Guidance
- 2025 sales growth narrowed to 8-11% (from prior range) at constant exchange rates due to lower GLP-1 treatment growth expectations in diabetes and obesity
- 2025 operating profit expected 4-7% at constant exchange rates, negatively impacted by DKK 8 billion restructuring costs
- 2026 impact: semaglutide patent expiry in certain international markets expected to have low single-digit negative impact; Akero acquisition expected to reduce operating profit growth by ~3 percentage points due to increased R&D costs
- Wegovy pill FDA decision expected by end of 2025 with launch readiness for early 2026; CagriSema submission and REDEFINE 4 readout expected first quarter 2026
Q&A themes
- Market share loss in GLP-1 market primarily attributed to market dynamics and Eli Lilly competition; management emphasized long-term volume opportunity and market expansion focus over share preservation
- Metsera acquisition rationale: differentiated assets complementary to internal pipeline addressing obesity as multiple diseases requiring diverse treatment options; deal structure reflects confidence in clinical data
- U.S. Wegovy prescription trends: ~270,000 weekly prescriptions (down from 280,000 in prior quarter); competition and compounding (~1 million patients) remain headwinds; cash channel expansion through partnerships (Costco, Walmart, GoodRx) key strategy
- Medicare and Medicaid access: ~30 million Medicare-age obesity patients represent important opportunity; several states announced Medicaid coverage changes for 2026 due to budget constraints; company pursuing improved access through reduced prior authorization and utilization management
Risks
- Global GLP-1 market share declining significantly (9 percentage points lost over 12 months); intensifying competition in both diabetes and obesity across U.S. and international operations affecting pricing and volumes
- Wegovy pricing pressure and access barriers: commercial insurance coverage remains challenging, Medicaid coverage expected to decline in certain states in 2026, and compounded GLP-1 usage estimated at >1 million patients
- Metsera acquisition completion uncertain; regulatory review by FTC referenced in Q&A; deal structure with 50% nonvoting preferred stock creates execution and control risks
FY2025 Q22025-08-06
Earnings calls
AI summary
mixedNovo Nordisk delivered 18% sales growth and 29% operating profit growth in H1 2025, with 46 million patients now on its diabetes and obesity treatments. However, the company lowered its full-year 2025 outlook, citing lower-than-expected growth for Wegovy in the U.S. obesity market, Ozempic in the U.S. GLP-1 diabetes market, and Wegovy in select international markets. Updated 2025 guidance now projects 8-14% sales growth and 10-16% operating profit growth at constant exchange rates.
Key takeaways
- H1 2025 sales grew 18% at constant exchange rates; operating profit increased 29%; company now serving 46 million diabetes and obesity patients
- Full-year 2025 sales growth guidance reduced to 8-14% from prior guidance, driven by slower H2 expectations for Wegovy and Ozempic in U.S. and select IO markets
- Obesity care sales surged 58% H1 with Wegovy reaching 280,000 weekly prescriptions; compounding estimated at 1 million U.S. patients continues to impact penetration
- Wegovy penetration in U.S. cash channel at 10% following NovoCare Pharmacy launch; CVS National Template Formulary change in July shows early positive indicators
- R&D pipeline advances include amycretin advancing to Phase III (AMAZE program starting 2026), CagriSema Phase IIIb trial (REDEFINE 11) initiated, and Ozempic positive EMA opinion for peripheral arterial disease
Financial highlights
- H1 2025 sales growth: 18% at constant exchange rates; operating profit growth: 29% at constant exchange rates
- Gross margin decreased to 83.4% from 84.9% in 2024, primarily due to Catalent amortization/depreciation and capacity expansion costs
- Free cash flow declined to DKK 33.6 billion from DKK 41.3 billion in H1 2024 due to increased CapEx (DKK 28.1 billion vs. DKK 18.9 billion)
- Interim dividend increased 7% to DKK 3.75 per share; DKK 36.5 billion returned to shareholders in H1 2025
Guidance
- 2025 sales growth guidance: 8-14% at constant exchange rates (previously higher); operating profit growth: 10-16% at constant exchange rates
- Free cash flow expected DKK 35-45 billion in 2025; CapEx still expected around DKK 65 billion in 2025; effective tax rate 21-23%
- Wegovy MASH indication regulatory decision expected Q3 2025; oral semaglutide for obesity expected to launch in U.S. in 2026 without supply restrictions
- AMAZE Phase III program with amycretin to start early 2026; REDEFINE 11 Phase IIIb trial with CagriSema underway; low-single-digit LOE impact to group sales expected in select IO markets
Q&A themes
- CVS formulary conversion impact on Wegovy prescriptions progressing according to plan with early positive July indicators; multiple commercial efforts contributing to recent uptake increases
- China GLP-1 market destocking in Q2 due to prior year Wegovy launch build and timing; company confident in future growth given 200 million obesity and 100 million diabetes populations
- Capacity now supporting high pace of Wegovy IO launches (35 markets vs. 20 at year-start); oral sema obesity expected to launch non-supply-restricted in 2025 U.S.
- Unlawful compounding remains priority; company pursuing multiple legal actions with FDA dialogue ongoing; litigation options being explored but not ruled out
Risks
- Unlawful semaglutide compounding persists with estimated 1 million U.S. patients, continuing to impact Wegovy cash channel penetration and branded obesity market growth
- Guidance reduction indicates softer than expected H2 2025 demand for key products; uncertainty around gross-to-net adjustments (DKK 100B+ rebate provision) and volatile obesity market could move results within guidance range
- R&D pipeline includes multiple high-risk programs (e.g., Alzheimer's trials EVOKE/EVOKE+ described as 'high risk, high reward'); market competition from other GLP-1 products intensifying with competing trial data
FY2025 Q12025-05-07
Earnings calls
FY2024 Q42025-02-05
Earnings calls
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.- US FDA orders new eye risk warnings for Ozempic, Zepbound
- GLP-1 drugs help control prediabetes better than current standard medicine
- Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
- Novo Nordisk's CFO Karsten Munk Knudsen to leave company
- Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
- US FDA extends review of Novo Nordisk's hemophilia drug over facility issues
- Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
- Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
- Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
- China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Company data
Company intelligence
Updated: Nov 13, 2026, 06:45 AM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Maziar Mike Doustdar
- Employees
- 68,794
- IPO date
- Apr 30, 1981
- Country
- DK
- Exchange
- New York Stock Exchange
Altman Z-scorei3.72
Piotroski scorei7/9
Overall ratingiA-
Owner earningsiDKK 29.91BDKK 6.76 per share
ESG risk ratingiB-Industry rank: 28/28
Rating factors
- Return on equityi
- 5/5
- Return on assetsi
- 5/5
- Debt to equityi
- 2/5
- Price to earningsi
- 3/5
- Price to booki
- 2/5
Company press releases
Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routinePRNewsWireNovo Resources Releases Updated Corporate PresentationGlobeNewsWireNovo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026PRNewsWireNovo Nordisk A/S - share repurchase programmeGlobeNewsWireNovo provides update on the denecimig Biologics License Application (BLA) in the USGlobeNewsWireNovo Resources Releases Updated Corporate PresentationGlobeNewsWire
Congressional disclosures
Senate
Alan ArmstrongPurchase · $15,001 - $50,000Disclosed: Jul 21, 2026Thomas Hawley TubervilleSale (Full) · $15,001 - $50,000Disclosed: Feb 14, 2024Tommy TubervilleSale (Full) · $15,001 - $50,000Disclosed: Feb 14, 2024Thomas Richard CarperPurchase · $1,001 - $15,000Disclosed: May 17, 2021Thomas R. CarperPurchase · $1,001 - $15,000Disclosed: May 17, 2021
House
Kevin HernSale · $1,001 - $15,000Disclosed: Sep 28, 2026Kevin HernSale (Full) · $1,001 - $15,000Disclosed: Sep 25, 2026Kevin HernSale · $1,001 - $15,000Disclosed: Sep 28, 2026Kevin HernSale (Partial) · $1,001 - $15,000Disclosed: Sep 25, 2026Scott FranklinPurchase · $1,001 - $15,000Disclosed: Sep 18, 2026
Market cap history
$179.07B-12.8%Aug 2026 – Nov 2026
Latest: $179.07B · 2026-11-12High: $207.76B · 2026-08-24Low: $166.23B · 2026-10-05
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| PPH | 5.47% | 1.5M |
| AVDE | 0.3% | 1.5M |
| WCMI | 1.64% | 838.1K |
| FENI | 0.28% | 808.8K |
| PID | 2.01% | 440.3K |
| LIFE.TO | 5.07% | 318.3K |
| RODM | 0.7% | 294.4K |
| AVIV | 0.46% | 236.2K |
| APIE | 0.79% | 218.3K |
| OZEM | 11.79% | 165.1K |
| AQEC | 0.63% | 92.9K |
| NVOH | 94.23% | 89.5K |
Analyst track record
How the analysts covering NVO have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 54 | 173 |
| Analysts | 11 | 23 |
| Buy / hold / sell | 11 / 41 / 2 | 98 / 68 / 7 |
| Upgrades / downgrades / initiations | 1 / 8 / 0 | 6 / 15 / 6 |
| Price targets hit / missed | 4 / 43 (9%) | 4 / 138 (3%) |
| Avg. return after a rating (TipRanks) | -14.4% | -43.8% |
| Best / worst call | +1.6% / -41.9% | +1.6% / -81.0% |
After buy calls on this stock: median 21-day move +2.3% vs S&P 500 +0.1% (n = 100)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Michael NedelcovychTD Cowen13% hit rate on this stock · 16 targets measuredHoldtarget $42.00Sep 22, 2026
- Evan SeigermanBMO Capital0% hit rate on this stock · 19 targets measuredHoldtarget $40.00Nov 4, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 4, 2026 | Evan SeigermanBMO CapitalNov 4, 2026 | HoldMaintained | $40.00↗ | article ↗ |
| Oct 13, 2026 | Kerry HolfordBerenberg BankOct 13, 2026 | HoldMaintained | $47.00↗ | article ↗ |
| Oct 12, 2026 | Evan SeigermanBMO CapitalOct 12, 2026 | HoldMaintained | $40.00↗ | article ↗ |
| Oct 7, 2026 | Evan SeigermanBMO CapitalOct 7, 2026 | HoldMaintained | $47.00↗ | article ↗ |
| Sep 29, 2026 | Evan SeigermanBMO CapitalSep 29, 2026 | HoldMaintained | $47.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 13, 2026 · 54 ratings
Frequently asked questions
Where can I trade NVO perpetual futures?
Novo Nordisk A/S (NVO) perpetual futures trade on 16 crypto venues, including BingX, XT.com, Binance. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade NVO around the clock?
Yes. Unlike the underlying stock, NVO perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on NVO perpetuals?
Right now the NVO perp funding rate is +13.6% annualized (venue median), ranging from 0.0% to +24.1% across 16 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the NVO perp price compare to the Novo Nordisk A/S stock?
The venue-median NVO perp mark is $41.1 versus a reference stock price of $41.1, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a NVO perpetual future?
A NVO perpetual is a derivative that tracks the price of Novo Nordisk A/S with no expiry date. It lets you take long or short exposure to Novo Nordisk A/S on crypto venues, around the clock.
What is NVOUSDT perpetual?
NVOUSDT is the symbol most crypto exchanges use for the Novo Nordisk A/S perpetual settled in USDT (Tether). It tracks the NVO share price through an index, trades 24/7 with leverage and never expires.
Embed this asset
<a href="https://perpequities.com/stocks/nvo-perp"><img src="https://perpequities.com/badge/nvo-perp.svg" width="240" height="64" alt="NVO perpetuals · perpequities.com" loading="lazy"></a>